Ro vs Henry Meds for Semaglutide: 2026 Comparison

Ro vs Henry Meds for Semaglutide: 2026 Comparison

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.

Ro and Henry Meds tied on compounded semaglutide pricing — both at $149/month — but they are no longer the same kind of company. Ro has pivoted toward FDA-approved brand-name medications and is phasing out its compounded semaglutide offering. Henry Meds has not made that shift. Choosing between them in 2026 means choosing a stance on the compounded vs. brand-name question as much as it means picking a provider.

Ro and Henry Meds both charge $149/month for compounded semaglutide, but the more meaningful difference in 2026 is that Ro is transitioning toward FDA-approved brand-name GLP-1s while Henry Meds remains exclusively compounded. Choosing between them is a brand-vs-compounded decision as much as a provider comparison.

How do Ro and Henry Meds compare on price?

Compounded semaglutide is $149/month at both platforms. For any other medication, the comparison diverges completely: Ro has brand-name options that Henry Meds does not carry, and Henry Meds has compounded tirzepatide that Ro does not offer.

Pricing last verified April 2026. We update pricing data monthly.

	Ro	Henry Meds
Compounded semaglutide	$149/mo (phasing out)	$149/mo
Oral Wegovy (4mg)	$199/mo	Not available
Oral Wegovy (9–25mg)	$299/mo	Not available
Compounded tirzepatide	Not available	$349/mo
Brand Zepbound	$299/mo (LillyDirect)	Not available
Loyalty discount	No	$129/mo after 6 months
Consultation	Free	Free
Shipping	Free	Free

Henry Meds has one pricing advantage for long-term patients: a loyalty discount that drops compounded semaglutide to $129/month after six months of continuous use — a $240/year saving versus the standard rate. Ro has no equivalent. For patients who plan to stay on compounded semaglutide indefinitely, Henry Meds becomes the cheaper option over time.

What medications does each provider offer?

Henry Meds is exclusively compounded — they carry compounded semaglutide and compounded tirzepatide, nothing else. Ro's menu has shifted toward brand-name: oral Wegovy (two dose tiers), brand-name Zepbound via LillyDirect, and compounded semaglutide that Ro is in the process of phasing out.

Compounded tirzepatide — the dual GIP/GLP-1 agonist — is only available at Henry Meds between these two providers. Any FDA-approved finished GLP-1 product is only available through Ro.

Medication	Ro	Henry Meds
Compounded semaglutide (injectable)	✅ (phasing out)	✅
Oral Wegovy 4mg (brand)	✅	❌
Oral Wegovy 9–25mg (brand)	✅	❌
Brand Zepbound (tirzepatide)	✅ (LillyDirect)	❌
Compounded tirzepatide	❌	✅ ($349/mo)

Oral Wegovy is particularly relevant for needle-averse patients or frequent travelers who find weekly injections inconvenient. Clinical note: oral semaglutide absorption is highly sensitive to food timing. The medication must be taken on an empty stomach with no more than four ounces of water, with no food or other medications for at least 30 minutes after dosing. Bioavailability is approximately 1%, which is why the oral dose is substantially higher than the injectable dose to achieve comparable blood levels.

What is the regulatory difference between Ro and Henry Meds?

This is the most consequential difference heading into 2026. Ro voluntarily exited the compounded semaglutide market and is pivoting toward FDA-approved medications. Henry Meds has not made that transition and continues to offer both compounded semaglutide and compounded tirzepatide.

Both platforms, while they offered or currently offer compounded medications, use 503B-registered outsourcing facilities — FDA-inspected pharmacies that must comply with current Good Manufacturing Practices (cGMP). This is a meaningfully higher quality standard than traditional 503A compounding pharmacies.

The regulatory context has tightened since 2025. The FDA determined that semaglutide shortage conditions no longer justify broad compounding exemptions, and enforcement actions against compounding pharmacies have accelerated. Compounded tirzepatide faced a more urgent timeline: the FDA's compounded tirzepatide enforcement deadline passed in April 2025. Henry Meds continues to offer both products. The long-term regulatory availability of compounded GLP-1s is not guaranteed.

Ro's pivot to brand-name medications eliminates this regulatory exposure for patients who use their platform. Whether that matters to you depends on your risk tolerance and how long you plan to stay on GLP-1 medication.

503B facilities are FDA-inspected and quality-controlled — compounded medications from them are not inherently unsafe. Regulatory continuity is the exposure: Ro has chosen brand-name medications to remove it; Henry Meds has not.

How do Ro and Henry Meds work as platforms?

Both are fully asynchronous — no video consultations at either as a default. The process is identical in structure: complete an online health assessment, a licensed provider reviews it, medication ships if approved. The differences are in speed and what the platform offers beyond the prescription.

	Ro	Henry Meds
Consultation model	Async-primary, some video on request	Async only
Provider review time	~24 hours	24–48 hours
First shipment	3–5 business days	3–5 business days
Lab testing	No	No
Coaching / behavioral support	No	No
Insurance navigation	Yes (brand medications)	No

Ro reviews prescriptions slightly faster (~24 hours vs 24–48 hours for Henry Meds), though first shipment timing is comparable at both. Neither platform includes metabolic labs, lifestyle coaching, or video consultations as standard features. Both are medication-delivery platforms, not comprehensive weight management programs.

Ro's insurance navigation support — added in 2025 — is a meaningful differentiator for patients pursuing brand-name medications. Ro assists with prior authorization paperwork and coverage verification for brand Wegovy and Zepbound. Henry Meds is cash-pay only with no insurance support of any kind.

What dosing protocols do Ro and Henry Meds use?

Both providers follow standard titration protocols established in clinical trials:

Semaglutide: Starting dose 0.25mg/week, titrated upward every four weeks based on tolerance. Typical maintenance dosing ranges from 1.0mg to 2.4mg/week. The STEP 1 trial demonstrated 14.9% mean body weight loss at 2.4mg/week over 68 weeks (Wilding et al., NEJM 2021).

Tirzepatide (Henry Meds only): Starting dose 2.5mg/week, titrated upward by 2.5mg every four weeks based on tolerance. Maximum dose 15mg/week. SURMOUNT-1 demonstrated 22.5% mean body weight loss at the 15mg dose over 72 weeks (Jastreboff et al., NEJM 2022).

Both platforms handle titration through async provider messaging — no video consultation is standard at either. Patients with significant side effects or complex titration questions should expect communication by app message, not phone or video call.

Who is Ro best for?

• Patients who want FDA-approved brand-name medications — Ro's oral Wegovy and brand Zepbound access gives patients a clear telehealth path to approved finished products
• Needle-averse patients — Oral Wegovy at $199/month through Ro is one of the most accessible oral semaglutide options in telehealth
• Patients with insurance coverage for GLP-1s — Ro's prior authorization support for brand-name medications helps patients whose plans cover weight management
• Patients who value platform maturity — Ro has been operating since 2017 with over one million patients treated; Henry Meds launched in 2021
• Patients who want to avoid regulatory uncertainty — Ro's exit from compounding eliminates exposure to FDA enforcement risk on compounded GLP-1s

Who is Henry Meds best for?

• Patients who want compounded tirzepatide at a cash-pay price — $349/month is far below brand Zepbound retail; Ro does not offer this product
• Long-term compounded semaglutide patients — The $129/month loyalty price after six months makes Henry Meds the cheapest ongoing option between the two for semaglutide
• Budget-focused cash-pay patients who understand the compounded vs. brand tradeoffs and are not seeking insurance navigation
• Self-directed patients who have made a deliberate choice to continue with compounded medications and are not concerned by the evolving regulatory environment

How We Evaluated

We compared Ro and Henry Meds across five dimensions: all-in monthly pricing at each medication tier, formulary breadth and regulatory status, clinical onboarding speed and titration protocol, platform features (insurance navigation, lab testing, coaching), and company profile (founding year, patient volume, operational infrastructure). Pricing was verified against each provider's public website and checkout flow in April 2026. Telehealth Ally has no commercial relationship with either provider — editorial assessments are independent.

Summary Table

Factor	Ro	Henry Meds
Compounded semaglutide	$149/mo (phasing out)	$149/mo
Compounded tirzepatide	❌	✅ $349/mo
Oral Wegovy (brand)	✅ $199–$299/mo	❌
Brand Zepbound	✅ $299/mo	❌
Insurance navigation	✅	❌
Loyalty discount	❌	✅ $129/mo at 6+ months
Founded	2017	2021
Regulatory direction	Moving to brand-name	Staying compounded
Our rating	4.0/5	3.5/5

Frequently Asked Questions

Which is cheaper: Ro or Henry Meds? Both charge $149/month for compounded semaglutide, making them tied at entry. Henry Meds becomes cheaper long-term — the loyalty discount drops their compounded semaglutide to $129/month after six months, a $240/year advantage. For tirzepatide, Henry Meds is the only option between the two at $349/month compounded; Ro's brand Zepbound access is insurance-dependent and not available at a flat cash-pay rate.

Does Henry Meds offer tirzepatide that Ro does not? Yes. Henry Meds offers compounded tirzepatide at $349/month. Ro does not offer compounded tirzepatide. Ro can assist with brand-name Zepbound through insurance prior authorization, but that requires coverage and approval — it is not available as a straightforward cash-pay option the way Henry Meds' compounded version is.

Is Ro or Henry Meds better for compounded semaglutide? Both offer compounded semaglutide at $149/month from 503B-registered pharmacies with similar clinical protocols. Ro has a longer operational track record (founded 2017 vs Henry Meds' 2021). Henry Meds offers a loyalty discount to $129/month after six months. For first-time GLP-1 patients who want an established platform, Ro's history gives it a slight edge. For cost-focused patients planning to stay on compounded semaglutide long-term, Henry Meds' loyalty pricing is the better deal.

Can I switch from Henry Meds to Ro? Yes. Switching GLP-1 providers is medically straightforward — you complete a new intake assessment at Ro, disclose your current dose and medication history, and receive a new prescription at the equivalent or appropriate starting dose. There is no medical barrier. Practically, time the switch to avoid gaps in medication supply between your last Henry Meds shipment and first Ro delivery.

Which is more regulated: Ro or Henry Meds? Ro is moving toward FDA-approved finished drug products (oral Wegovy, brand Zepbound), which carry full FDA approval as finished medications with standardized manufacturing and clinical trial data. Henry Meds remains on compounded medications from 503B-registered outsourcing facilities — FDA-inspected but not FDA-approved as finished products. Both use 503B facilities for any compounded products, which is the more rigorous tier of compounding oversight. For patients who prioritize regulatory certainty, Ro's brand-name pathway provides it in a way compounded products do not.

Related Resources

• Henry Meds Review — Full Henry Meds analysis
• Ro Weight Loss Review — Full Ro Body Program analysis
• Henry Meds vs Hims for GLP-1 — Henry Meds head-to-head with another competitor
• Sesame vs Henry Meds for Semaglutide — Marketplace model vs subscription pricing
• Compounded Semaglutide vs Brand Wegovy — The brand-vs-compounded tradeoff explained
• Ro vs Hims vs Henry Meds for GLP-1 — Three-way provider comparison